This article has not been updated since February 2014. For updated information, reference Related Articles.
Recently, a drug marketed and approved by the FDA is getting a lot of unwanted attention. Risperdal, an anti-psychotic drug used to treat schizophrenia, bipolar disorder, and irritability associated with autism, was marketed to doctors working with troubled children for uses not approved by the FDA in 2004. Eight whistle-blowers helped federal authorities uncover illicit activities by Johnson & Johnson involving the marketing of the drug.
The whistle-blowers wore hidden recording devices as Johnson & Johnson held marketing presentations at their national sales meetings and urged sales representatives to push Risperdal beyond its approved use. J&J marketed Risperdal for off-label uses and paid kickbacks to doctors and pharmacists to boost sales. Janssen, a subsidiary of J&J, pleaded guilty of misbranding Risperdal.
According to the 9-year FDA investigation, evidence proved J&J promoted Risperdal to elderly patients suffering from dementia and to children before the drug was approved by the FDA. On November 4, 2013, J&J agreed to pay $2.2 billion to resolve criminal and civil probes surrounding the marketing of Risperdal.
J&J has settled more than 1,000 claims, including 80 lawsuits claiming Risperdal caused gynecomastia. Gynecomastia is the development of abnormally large breasts in males. Research has shown that Risperdal can also cause lactation and uncontrolled body movements (tardive dyskinesia).
If you or your child has taken Risperdal and suffer from one of the devastating side effects, call one of our experienced drug injury lawyers today. Wilson Kehoe Winingham offers a free, confidential, consultation to discuss your injuries and your rights.
Risperdal® is a registered trademark of Johnson & Johnson, and is used here only to identify the product in question.